This study recommends developing a risk assessment tool for menorrhagia in primary healthcare settings, integrating hormonal markers such as FSH (> 10 IU/L), oestradiol outside normal cycle ranges, total testosterone (> 70 ng/dL), and prolactin (> 25 ng/mL). This evidence concerns the gene BRD2 and Menorrhagia.